(Q38434820)

3 September 2017

1 reference

title

Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma (English)

1 reference

3 September 2017

1 reference

Ian D Pavord

3

0 references

author name string

Bart Hilvering

series ordinal

1

1 reference

3 September 2017

Luzheng Xue

series ordinal

2

1 reference

3 September 2017

publication date

21 April 2015

1 reference

Therapeutic advances in respiratory disease

3 September 2017

published in

1 reference

3 September 2017

volume

9

1 reference

3 September 2017

issue

4

1 reference

3 September 2017

page(s)

135-145

1 reference

Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Interleukin 5 is protective during sepsis in an eosinophil-independent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Mepolizumab treatment in patients with severe eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Complex airway disease: an approach to assessment and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465815581279

21 January 2018

Identifiers

DOI

10.1177/1753465815581279

1 reference

3 September 2017

1 reference